coronavirus
 

During the developing COVID-19 pandemic, The Nuffield Department of Medicine is taking measures to prevent the spread of the disease. 

Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation.

This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions -

  • No public access to the University
  • On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines
  • Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place

Key Information for Staff

Latest News

The Ludwig Institute for Cancer Research welcomes cancer epigenetics researcher Yang Shi

The Ludwig Institute for Cancer Research welcomes cancer epigenetics researcher Yang Shi

Posted 01/07/2020

Yang Shi has been appointed a Member of the Ludwig Institute for Cancer Research to continue his research into chromatin, RNA modifications and cancer.  He joins NDM's Ludwig Institute from Harvard University, and is a world leader in the field of epigenetics, which explores how chemical modifications to chromatin—the combination of DNA and histone proteins—control the organisation and expression of the human genome.

The Duke of Cambridge visits Oxford Vaccine Centre

The Duke of Cambridge visits Oxford Vaccine Centre

Posted 25/06/2020
The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.  The Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway.  During his visit, The Duke was briefed about the Group’s work by NDM's Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity, who is leading the clinical trial team.
Oxford University Coronavirus Research Webinar

Oxford University Coronavirus Research Webinar

Posted 23/06/2020

Originally screened live on Friday 22nd May 2020, here is another chance to view the Vice-Chancellor, Professor Louise Richardson, being joined by Professor Richard Cornall, Head of the Nuffield Department of Medicine, to talk about the University's research into the COVID-19 virus.

Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19

Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19

Posted 16/06/2020
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment).  NDM's Peter Horby, Professor of Emerging Infectious Diseases and one of the Chief Investigators for the trial, said, ‘Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result'.

News Archive

 Research Highlight

The natural history and transmission potential of asymptomatic SARS-CoV-2 infection

The natural history and transmission potential of asymptomatic SARS-CoV-2 infection

Posted 09/06/2020

Dr Le Van Tan and colleagues from OUCRU, Vietnam, demonstrate that 43% of quarantined people who were RT-PCR positive for SARS-CoV-2 were asymptomatic, but potentially contagious. The results emphasize the importance of contact tracing, airport quarantine and RT-PCR screening for SARS-CoV-2 among isolated people in controlling the ongoing pandemic.

View Research Highlights

Public Engagement

Podcast: Meet our Researchers

sarahn gilbert

Viral vectored vaccine development

Professor Sarah Gilbert has been making and testing vaccines designed to induce T cell responses for ten years, chiefly using antigens from malaria and influenza. Based at the Jenner Institute, several of the vaccines developed in Professor Gilbert’s laboratory have progressed into Clinical Trials.

View podcast